Last Posted: Jan 24, 2019
- An economic model of the cost-utility of pre-emptive genetic testing to support pharmacotherapy in patients with major depression in primary care.
Sluiter Reinier L et al. The pharmacogenomics journal 2019 Jan - Cost-effectiveness analysis of pharmacogenomics-guided clopidogrel treatment in Spanish patients undergoing percutaneous coronary intervention.
Fragoulakis Vasilios et al. The pharmacogenomics journal 2019 Jan - Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-Positive Non-Small Cell Lung Cancer in China.
Cai Hongfu et al. Clinical therapeutics 2019 Jan - Development and Standardization of an Improved Type 1 Diabetes Genetic Risk Score for Use in Newborn Screening and Incident Diagnosis.
Sharp Seth A et al. Diabetes care 2019 Jan - Big data in IBD: a look into the future.
Olivera Pablo et al. Nature reviews. Gastroenterology & hepatology 2019 Jan - Current Status and Future Opportunities in Lung Precision Medicine Research with a Focus on Biomarkers. An American Thoracic Society/National Heart, Lung, and Blood Institute Research Statement.
Wu Ann Chen et al. American journal of respiratory and critical care medicine 2018 Dec 198(12) e116-e136 - The contribution of genomics in the medicine of tomorrow, clinical applications and issues.
Laviolle Bruno et al. Therapie 2018 Dec - Value of genetic testing in the prevention of coronary heart disease events
Y Hynninen et al, PLOS One, January 2019 - Cost-effectiveness of a genetic test for breast cancer risk--response.
Folse Henry et al. Cancer prevention research (Philadelphia, Pa.) 2014 Apr 7(4) 476 - Evaluation of genotyping methods and the relative cost of pharmacogenomics.
De Monaco A et al. European review for medical and pharmacological sciences 2014 18(14) 2084-7
.jpeg)
No hay comentarios:
Publicar un comentario